drugset / Trial / NCT00390039

Efficacy and Safety of Intranasal Morphine for Pain After Elective Orthopedic Surgery

NCT00390039

Phase 3 Completed 256 enrolled Javelin Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Multiple-center, multiple-dose, randomized, double-blind, six-arm, active- and placebo-controlled study in patients with moderate to severe post-surgical pain from elective orthopedic surgery with safety observed for a total of 30 hours post first dose.

Timeline

Start
2006-05
Primary completion
2006-09
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Morphine Other / unclassified 7.5 mg Intranasal
Subject Morphine Other / unclassified 15 mg Intranasal

Indications

No indication recorded.